Navigation Links
Stopping smoking cessation treatments too soon may reduce odds of success for 45 percent of smokers
Date:9/1/2010

ters treated with varenicline, bupropion and with counseling alone [placebo], Gonzales explained, and appears to be a previously unreported and natural pattern of quitting for motivated smokers who seek treatment to quit.

"Had treatment been interrupted or discontinued for these 'delayed quitters,' opportunities for achieving continuous abstinence could have been lost for up to 45 percent of quitters who were ultimately successful," Gonzales said.

Gonzales and colleagues analyzed data from two identically designed, published studies (Gonzales et al. JAMA 2006 and Jorenby et al. JAMA 2006) conducted between June 2003 and April 2005. Participants included 2,052 generally healthy adult smokers who randomly received either a smoking cessation drug varenicline or bupropion or a placebo for 12 weeks of treatment plus 40 weeks of follow-up. All participants received brief smoking cessation counseling at clinic visits and investigators were blinded to the treatment assignments.

Successful quitters were defined as smokers who achieved continuous abstinence, not even one puff, for the last four weeks of treatment (weeks nine through 12). Among successful quitters, two groups were identified: "immediate quitters," smokers who quit and remained abstinent from their target quit date through the end of week 12; and "delayed quitters," smokers who had periods of smoking prior to attaining continuous abstinence for at least the last four weeks of treatment.

The overall end-of-treatment quit rates for the two studies were previously shown to be higher for varenicline, but in this analysis, the researchers found cumulative continuous abstinence increased similarly for all treatments during weeks three through eight. They also found quitting patterns among delayed quitters were similar regardless of whether they took varenicline, bupropion or received counseling only (placebo).

While delayed quitters did not fare quite as well as immed
'/>"/>

Contact: Tamara Hargens-Bradley
hargenst@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. The Infrex Plus is Revolutionizing Pain Control by Stopping Pain & Eliminating Drugs for Chronic Pain Patients Who Suffered For Years
2. Non-IV-administered medication just as effective in stopping seizures
3. New Report: $1 Cigarette Tax Increase Would Raise $418.8 Million for Texas and Cut Youth Smoking
4. New Report: $1 Cigarette Tax Increase Would Raise $18.6 Million for Montana and Cut Youth Smoking
5. New Report: $1 Cigarette Tax Increase Would Raise $24.8 Million for Wyoming and Cut Youth Smoking
6. New Report: $1 Cigarette Tax Increase Would Raise $43.3 Million for Utah and Cut Youth Smoking
7. New Report: $1 Cigarette Tax Increase Would Raise $113.9 Million for Colorado and Cut Youth Smoking
8. New Report: $1 Cigarette Tax Increase Would Raise $65.3 Million for Iowa and Cut Youth Smoking
9. Quitting smoking especially difficult for select groups
10. New intervention helps Latino parents of asthmatic children quit smoking
11. Warning: Immigrating to North America may foster smoking in children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... A group of nine authors involved with ... Inspire Award at DIA’s upcoming Annual Meeting. DIA’s Global ... their leadership, level of excellence, and commitment to service ... of the Author(s) of the Year Award, which acknowledges ... made a significant impact in advancing medical product development, ...
(Date:6/3/2015)... 03, 2015 Z-Medica®, LLC, a leading ... June has been designated as National Safety Month by ... AZ. Police Department for its commitment to public safety. ... their Individual First Aid Kits (IFAK) over 100 times ... shootings, stabbings or traffic accidents. Each kit is equipped ...
(Date:6/3/2015)... June 03, 2015 Researchers at the ... for mesothelioma and say the tried-and-true marker mesothelin is ... an article on the research. Click here to ... National Center for Asbestos Related Diseases say, even though ... it is still preferable to fibulin-3 for identifying mesothelioma. ...
(Date:6/3/2015)... According to an article published on May14th by ... pills which actually contained the potent addictive drug fentanyl. ... even sported the “A/215” imprint common on real oxycodone ... oxycodone to be exceptionally critical of their prescriptions—especially those ... on the street. Fentanyl is an opiate-based narcotic and ...
(Date:6/3/2015)... Atlanta, GA (PRWEB) June 03, 2015 ... A in Duluth, GA will celebrate its grand opening ... 2015. , The first prosthetic center of its kind ... and their family unmatched care and outcomes through use ... Keith Watson, CPO & CEO of Fourroux Prosthetics, states, ...
Breaking Medicine News(10 mins):Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 4Health News:Z-Medica Commends Tucson Police Department for Trauma Kit Utilization 2Health News:Analysis Reveals Gold Standard Mesothelioma Biomarker Still the Best, According to Surviving Mesothelioma 2Health News:Fake Oxycodone Pills of Fentanyl Discovered in Tennessee by Police 2Health News:Fake Oxycodone Pills of Fentanyl Discovered in Tennessee by Police 3Health News:Fourroux Prosthetics Atlanta to Have Grand Opening Gala & Ribbon Cutting Ceremony 2
... , , WASHINGTON, July 22 There ... (H.R. 3200) that concern citizens who care greatly about the freedom to ... bill: , , * Eliminates Existing Private ... "Acceptable" to the Federal Government, But Is Just Fine With You ...
... , , , ... consecutive year, Regence won four bronze (second-place) Telly Awards for originally created ... Web site for Regence members. , , ... of non-news and advertising video production; Regence,s videos were selected from more ...
... , SAN DIEGO, July 22 ... it intends to offer, subject to market and other conditions, 9,000,000 ... connection with this offering, Orexigen expects to grant to the underwriter ... of common stock to cover overallotments, if any. All of the ...
... , LANCASTER, Pa., July 22 The Board of Directors for Herley ... management leadership. , , , ... Lieberman named Chairman of The Board , Richard Poirier ... Walker (Ret.) to continue as Vice Chairman of the Board , ...
... Finding may lead to new treatments, researcher says , WEDNESDAY, ... thrombomodulin, which is involved in blood clotting and preventing cell ... new Canadian study suggests. , The finding might lead to ... about 300 children affected by it in the United States, ...
... such program in world started in Australia , WEDNESDAY, ... readying its first human trials of an experimental vaccine ... announced Wednesday. , Two possible vaccines will be tested ... of the National Institute of Allergy and Infectious Diseases ...
Cached Medicine News:Health News:Mandate for Health Insurance: Inconvenient Truths About How It Will Affect You and Your Family 2Health News:Regence Wins Four Telly Awards for Health and Wellness Videos 2Health News:Orexigen(R) Therapeutics Announces Proposed Public Offering of Common Stock 2Health News:Herley Industries, Inc. Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22, 2009 Conference in New York 2Health News:Herley Industries, Inc. Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22, 2009 Conference in New York 3Health News:Herley Industries, Inc. Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22, 2009 Conference in New York 4Health News:Herley Industries, Inc. Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22, 2009 Conference in New York 5Health News:Gene Mutation Could Be Key to Rare Blood Vessel Disease 2Health News:Gene Mutation Could Be Key to Rare Blood Vessel Disease 3Health News:U.S. Swine Flu Vaccine Trials Set to Begin 2Health News:U.S. Swine Flu Vaccine Trials Set to Begin 3Health News:U.S. Swine Flu Vaccine Trials Set to Begin 4Health News:U.S. Swine Flu Vaccine Trials Set to Begin 5Health News:U.S. Swine Flu Vaccine Trials Set to Begin 6Health News:U.S. Swine Flu Vaccine Trials Set to Begin 7Health News:U.S. Swine Flu Vaccine Trials Set to Begin 8Health News:U.S. Swine Flu Vaccine Trials Set to Begin 9Health News:U.S. Swine Flu Vaccine Trials Set to Begin 10Health News:U.S. Swine Flu Vaccine Trials Set to Begin 11Health News:U.S. Swine Flu Vaccine Trials Set to Begin 12Health News:U.S. Swine Flu Vaccine Trials Set to Begin 13
(Date:6/3/2015)... 3, 2015 AVT, Inc. (OTC Markets: AVTC) ... systems, announced today that their customer, Pharmabox, has introduced ... self-service kiosk carries over 140 top selling brand name ... Walgreen,s or Rite Aid-type store. As ... Miami -based Pharmabox worked with AVT ...
(Date:6/3/2015)... DIEGO , June 3, 2015  Halozyme ... a global collaboration and license agreement with AbbVie ... combining proprietary AbbVie compounds with Halozyme,s ENHANZE ™ ... of the agreement, Halozyme will receive an initial ... approximately $130 million for each of up to ...
(Date:6/3/2015)... 3, 2015 According to ... Peripheral Vascular Devices Market (Embolic Protection, Chronic Total ... Grafts, IVC Filters, Stents, Balloons and Accessories) - ... Cardiology and Peripheral Vascular Devices Market is expected ... a CAGR of 7.4% from 2014 to 2019. ...
Breaking Medicine Technology:Pharmabox Introduces New Concept with a Boldly Designed Automated Retailing System 2Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie 2Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie 3The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 2The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 3The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 4
... Inc. (NYSE: VRX ) (TSX: VRX) today announced ... Internet webcast along with a slide presentation on Thursday, February ... discuss results for the 2010 fourth quarter and full year. ... is (877) 295-5743, confirmation code 41335702.  International callers should dial ...
... PARK, Calif., Feb. 15, 2011 ForteBio®, Inc., a ... of biotherapeutic and pharmaceutical products, today announced the launch ... new Dip and Read Protein L Biosensor for use ... widen the scope and utility of the company,s flagship ...
Cached Medicine Technology:Valeant Pharmaceuticals to Announce 2010 Fourth Quarter and Full Year Results on February 24, 2011 2ForteBio Launches New Octet® RED96 System and Dip and Read™ Protein L Biosensor 2
... product solutions were developed to assist in ... To maximize use of existing capital equipment, ... the productivity of their employees, organizations are ... their valuable assets and ensure those assets ...
... Mobile Location-ID™ offers a for asset tracking electronically. ... to all the assets that will be tracked. ... equipped with a reader, antenna, and a portable ... small as 10 inches x 6 inches. One ...
Radianse indoor positioning supports healthcare asset management with a way to locate medical equipment, devices and other portable assets....
... provides hospitals with a suite ... all their supplies, drugs, assets, ... remove all manual compliance from ... accurately. iRIS, or Intelligent Radio-Frequency ...
Medicine Products: